U.S., Dec. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07309185) titled 'Adebrelimab Combined With Famitinib and Irinotecan in Advanced Gastric Cancer After Failure of First-Line Therapy' on Dec. 11.
Brief Summary: This study employs a randomized, controlled, exploratory clinical trial design, with a planned enrollment of 66 patients who have previously failed systemic chemotherapy for recurrent/metastatic gastric cancer,
Study Start Date: July 24, 2024
Study Type: INTERVENTIONAL
Condition:
Stomach Neoplasms
Intervention:
DRUG: Adebrelimab
Adebrelimab Injection: 1200mg, i.v.gtt, d1,
Once every 3 weeks, continue medication until disease progression, toxicity intolerance, initiation of new anti-tum...